Imagabalin Explained

Imagabalin (INN, USAN; PD-0332334) was an investigational drug that acts as a ligand for the α2δ subunit of the voltage-dependent calcium channel,[1] with some selectivity for the α2δ1 subunit over α2δ2.[2] It was under development by Pfizer as a pharmaceutical medication due to its hypothesized anxiolytic, analgesic, hypnotic, and anticonvulsant-like activity. It reached phase-III clinical trials for treatment of generalized anxiety disorder; however, the trials were terminated by the manufacturer.[3] [4] [5] [6] The drug is no longer under development.

See also

Notes and References

  1. Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA . Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: basic characterization and drug pharmacology . Brain Research . 1401 . 1–9 . July 2011 . 21664606 . 10.1016/j.brainres.2011.05.025 . 3197737 .
  2. Therapies in the Pipeline for Sleep Disorders: Focus on Novel Mechanisms and Disease Models . Larry Ereshefsky . 2008 . 11 . 2012-04-22 .
  3. Web site: Pfizer. 2012-11-09. A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study Of PD 0332334 And Paroxetine Evaluating The Efficacy And Safety Of PD 0332334 For The Treatment Of Generalized Anxiety Disorder. 2020-09-08. 2021-03-28. https://web.archive.org/web/20210328220724/https://www.clinicaltrials.gov/ct2/show/NCT00658008. live.
  4. Web site: Pfizer. 2012-11-09. A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study Of PD 0332334 And Paroxetine Evaluating The Efficacy And Safety Of PD 0332334 For The Treatment Of Generalized Anxiety Disorder. 2020-09-08. 2021-03-30. https://web.archive.org/web/20210330075157/https://www.clinicaltrials.gov/ct2/show/NCT00658372. live.
  5. Web site: Pfizer. 2012-11-09. A Phase 3, Randomized, Double-Blind, Parallel Group, 10-Week Placebo Controlled Fixed Dose Study of PD 0332334 and Paroxetine Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder. 2020-09-08. 2021-03-31. https://web.archive.org/web/20210331014217/https://www.clinicaltrials.gov/ct2/show/NCT00658762. live.
  6. Web site: Pfizer. 2012-11-09. A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder. 2020-09-08. 2021-04-01. https://web.archive.org/web/20210401114311/https://www.clinicaltrials.gov/ct2/show/NCT00735267. live.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Imagabalin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.